NanoViricides Inc. (NNVC): Genentech just granted a priority review...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Re: None

Thursday, 02/09/2012 2:44:08 PM

Thursday, February 09, 2012 2:44:08 PM

Genentech just granted a priority review for PERTUZOMAB. I sure hope one is in the not to distant future for NNVC.

Keep Last Read

Next 10 Prev Next

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM

InvestorsHub NewsWire

Only $200 per official company press release!